Sanofi-Aventis's Prowl for New Insulin, Could it be Biodel's Linjeta?
Sanofi-Aventis's Prowl for New Insulin, Could it be Biodel's Linjeta?
Last week, Sanofi-Aventis (NYSE: SNY) confirmed that it is on the prowl for diabetes partnerships. Bloomberg reported statements made by Riccardo Perfetti, the Senior Medical Director for Sanofi-Aventis’ diabetes unit, that Sanofi-Aventis may unveil “at least another couple critical partnerships” in diabetes in the months to come.